KRYS
Krystal Biotech Inc
NASDAQ: KRYS · HEALTHCARE · BIOTECHNOLOGY
$312.88
-2.21% today
Updated 2026-06-05
Market cap
$9.37B
P/E ratio
42.57
P/S ratio
22.46x
EPS (TTM)
$7.47
Dividend yield
—
52W range
$128 – $331
Volume
0.3M
Krystal Biotech Inc (KRYS) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed KRYS price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$312.88
Today
Analyst consensus
$324.11
+3.59% · 12M
2030 Base
$681.52
+117.82% future
NPV today
$494.63
@ 7% WACC
12 analysts:
10 Buy2 Hold0 Sell
Management guidance
Management has not provided explicit multi-year revenue targets in available disclosures. CEO Krish Krishnan emphasized strong Vyjuvek commercialization momentum (32% YoY growth in Q1 2026 to $116.4M), international expansion (UK, EU, Japan approvals), and a robust pipeline with two registrational readouts in 2026 and two more in 2027. Implied guidance suggests confidence in sustained high-growth trajectory through 2027-2028 based on pipeline catalysts and geographic expansion.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
KRYS · Krystal Biotech Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$282.51
NPV today: $205.04
Base case (2030)
$681.52
NPV today: $494.63
Bull case (2030)
$1,346.54
NPV today: $977.29
WallStSmart.com
KRYS financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $0.4B | $0.6B | $0.9B | $1.3B | $1.6B | $2.0B |
| Revenue growth | 33.9% | 41.9% | 35.0% | 28.2% | 24.1% | 20.5% |
| Net margin | — | 42.0% | 37.0% | 32.4% | 32.8% | 31.6% |
| EPS | $6.85 | $8.50 | $11.20 | $14.10 | $17.50 | $21.00 |
| Diluted shares | — | 30M | 30M | 30M | 30M | 30M |
| Net debt | — | $-600.73M | $-274.15M | $197.57M | $778.16M | $1.50B |
| P/S multiple | — | 11.0x | 11.0x | 11.0x | 11.0x | 11.0x |
| Implied price (base) | — | $243.04 | $342.04 | $472.21 | $561.02 | $681.52 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $2.0B | $2.0B | $2.0B |
| P/S multiple | 5.0x | 11.0x | 21.0x |
| Diluted shares | 30M | 30M | 30M |
| Net debt | $1.50B | $1.50B | $1.50B |
| Implied P/E † | 14x | 33x | 64x |
| 2030 Price | $282.51 | $681.52 | $1,346.54 |
| NPV @ 7% | $205.04 | $494.63 | $977.29 |
† Implied P/E: Multiples remain elevated across all three scenarios because KRYS is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $681.52 base case
KRYS catalysts and risks
Growth catalysts
+ Vyjuvek geographic expansion (UK MHRA approval secured; additional international launches in pipeline)
+ Pipeline readouts: KB407 (CF gene therapy) and Hailey-Hailey registrational studies in 2026-2027
+ KB707 RMAT designation for NSCLC (advanced/metastatic) — potential oncology expansion
+ At-home Vyjuvek administration (FDA approved) — expanded patient accessibility and reimbursement potential
+ Multiple gene therapy programs across respiratory, ophthalmology, oncology, and aesthetics advancing through 2027
Key risks
- Vyjuvek revenue concentration risk: single product drives ~100% of current revenue; pipeline execution risk critical for diversification
- Reimbursement and payer coverage volatility: gene therapy reimbursement precedents still evolving; pricing pressure possible as competition emerges
- Clinical/regulatory setbacks: pipeline programs face typical biotech binary outcomes (failed trials, delayed approvals); two registrational readouts in 2026 create binary risk
- Competitive gene therapy landscape: emerging competitors (Sesen Bio, Homology Medicines, etc.) could compress pricing and market share assumptions
- Q1 2026 earnings quality caveat: $18M tax benefit inflated statutory profit; underlying operational earnings lower than reported; sustainability risk if one-off
- Quarterly revenue variability: treatment patterns and reimbursement lags create quarterly 'waviness' despite strong trend
Methodology · Krystal Biotech Inc 2030 stock forecast model
Krystal Biotech Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 12 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (2% cumulative for KRYS by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($1.50B by 2030) |
| 3. Time value | NPV calculated using 7% WACC (CAPM: beta 0.495) |
| 4. Multiple framework | P/S compresses with scale: bear 5.0x / base 11.0x / bull 21.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 21, 2026.
KRYS price target FAQ
What is the KRYS price target for 2030?
WallStSmart's Krystal Biotech Inc 2030 base case is $681.52 per share, with a bull case of $1,346.54 and bear case of $282.51. The NPV of the base case discounted to today at 7% WACC is $494.63.
How is the Krystal Biotech Inc 2030 stock forecast calculated?
The KRYS 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the KRYS price target account for dilution?
Krystal Biotech Inc is projected to grow diluted share count from 29M to 30M by 2030 (a 2% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 2%.
What is the analyst consensus on KRYS stock?
12 analysts cover KRYS with an average 12-month price target of $324.11. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.